Clinical Trial Update: Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2 study of talabostat with rituximab for advanced chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)
• Talabostat (talabostat)

Snippet

Sponsor: Point Therapeutics | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED